PGI7 Impact of Complications from Dysphagia on Hospital Charges in the United States  by Jensen, I.S. et al.
2009. Subjects had to be continuously enrolled and be 18 years of age. Cases had
to have at least one incident claim with a primary diagnosis of acute liver necrosis,
hepatitis, hepatic coma, hepatorenal syndrome, or coagulopathy. 3:1 controls
matched on age, gender, and geographic region were randomly chosen. Acetamin-
ophen maximum and average daily doses were calculated in a range of acute
periods (7, 20, and 30 days) and in the chronic one year prior period. Conditional
logistic regression was used to estimate the risk of acetaminophen exposure ad-
justed for comorbidities, other hepatotoxic drugs, and health system factors.
RESULTS: There were 1350 cases and 4050 controls with a mean age of 47.29 years
and 53.85% were male. 116 (8.59%) cases and 144 (3.56%) controls were exposed to
acetaminophen in the 30-day prior period with mean maximum daily doses of
3234.32 and 3021.40 mgs. Hepatotoxicity was associated with any acute acetamin-
ophen exposure that decreased with longer look back periods; 7 days (OR2.23,
p0.001), 30 days (OR1.84, p0.001). Cumulative dose in the year prior was not
associated with hepatotoxicity (OR1.05, p0.889). Acute maximum daily doses
4gms/day were associated with greater risks of hepatotoxicity (OR2.45,
p0.001).CONCLUSIONS:Acute exposure to prescription acquired acetaminophen
is associated with increased risk of hepatotoxicity, however use over longer
chronic periods was not. Further research is necessary before the safety of chronic
acetaminophen can be established.
PGI3
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OBJECTIVES: The National Institute for Health and Clinical Excellence set the guid-
ance review date for an updated health technology appraisal in the treatment of
Chronic Hepatitis B (CHB), including the use of entecavir, as February 2012. The
objective of this study was to summarize the published evidence on the clinical
efficacy and safety of CHB treatments, through a systematic identification of rele-
vant randomised controlled trials. METHODS: A systematic literature search of
Embase, Medline, Medline in process and Cochrane CENTRAL databases was con-
ducted based on a research protocol with pre-defined criteria. The search period
covered from inception of databases until March 2011. All searches were limited to
full publications in the English language pertaining to adults with CHB without HIV
co-infection or liver cirrhosis at baseline. The search strategy contains a mixture of
free text and index terms. Abstract review and data extraction were performed
independently by two members of the project team. The comparators of interest
were: Adefovir dipivoxil, Entecavir, Interferon alfa 2a, Interferon alfa 2b, Peginter-
feron alfa-2a, Peginterferon alfa-2b, Lamivudine, Tenofovir and Telbivudine. Any
of the comparisons versus placebo or compared to another drug listed, were
included. RESULTS: 2,994 articles were identified with 2,107 abstracts reviewed
according to the predefined inclusion criteria. A total of 178 full papers were or-
dered and 27 papers (n9,033) included in the final analysis. Extensive data was
extracted related to key patient population details, interventions used, baseline
characteristics, endpoint data at numerous time points (up to 24 months) and
adverse events. The methodological quality of trials was assessed using the Co-
chrane Collaboration’s tool for assessing risk of bias. CONCLUSIONS: Although the
literature base is mature in terms of number of RCTs, due to the number of treat-
ments available the evidence network is weak. From those results, further analysis
through a network meta-analysis, adjusting for cross-trial differences between
study populations, should be investigated.
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OBJECTIVES:To assess the cost effectiveness in Turkey of acute treatment of reflux
esophagitis (RE) with esomeprazole (ESO) 40mg once daily (od) followed by main-
tenance treatment with 20mg od versus acute treatment with pantoprazole (PA)
40mg od followed by maintenance treatment with 20mg od. METHODS: In the
present study, ESO and PA were compared in a decision analytic model in terms of
costs and effectiveness. To assess the effectiveness, probabilities for treatment
success, which was healing of RE during initial acute treatment or a relapse while
on maintenance treatment, were obtained from the randomized, double-blind,
multi-center EXPO study. Patients healed after initial four to eight weeks acute
treatment received 6 months maintenance treatment. Therefore, all patients were
followed for seven months in the model. Direct medical costs were assessed based
on the perspective of the health care provider. Association between RE and lost
work productivity was regarded as 5.3 hours per employed patient per week. Sen-
sitivity analyses were performed by using upper and lower 95% confidence inter-
vals of the clinical study effectiveness results, as well as by changing patient man-
agement assumptions. RESULTS: Probability of treatment success per patient in
the ESO and PA strategy was 83.4 % and 69.6 %, respectively after 7 months. Mean
direct medical costs per patient in the ESO and PA strategy were the same; 152 TL
in both strategies. Total costs included direct medical costs and indirect costs,
which consisted of work absence and reduced work productivity. Total costs for
ESO and PA strategy were 247TL and 274TL, respectively implying a cost-saving of
27TL for ESO. Sensitivity analyses supported stability of main findings for a range of
scenarios. CONCLUSIONS: When considering total costs from a societal perspec-
tive, results indicate that esomeprazole treatment is dominant; esomeprazole pro-
vided a better clinical effectiveness at lower costs.
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OBJECTIVES: To explore disease burden, economic impact, treatment landscape
and unmet medical needs in patients with IBS-C. METHODS: We conducted a
review of MEDLINE- and EMBASE-indexed and ‘grey’ literature (citeable material
that is often not published in peer-reviewed, indexed medical journals, e.g.,web-
based international treatment guidelines) published in the last decade (January
2000 to December 2010) pertaining to the epidemiological, clinical, economic, and
humanistic impact of IBS-C with a European country focus (France, Germany, Italy,
Spain, UK). RESULTS: Altogether 885 unique studies were identified; 106 were in-
cluded in the analysis. Among patients with IBS, the prevalence estimates of IBS-C
range from 24% to 44%. Comorbid conditions such as personality and psychological
traits and stress, are common. Patients with IBS-C have lower health-related qual-
ity of life (HRQoL) compared with the general population (18 studies); treatment of
IBS-C can improve HRQoL. The European societal cost of IBS-C is largely unknown;
no European cost-of-illness (COI) studies were identified specifically on IBS-C. In
the absence of European data, US data show IBS-C to be cost-intensive. Two cost
analyses demonstrated the substantial societal impact of IBS-C, with adult patients
experiencing reduced productivity at work or through work absenteeism (mean
number of days off work annually: 8.5 to 21.6 days) due to severe, disruptive symp-
toms. European and local IBS treatment guidelines (where available) offer similar
diagnostic/management recommendations; however, IBS-C treatment varies by
country. Current monotherapy options for treating IBS-C are suboptimal. 5-HT4
agonists have been evaluated for IBS-C; however, they have been associated with
ischaemic colitis or a lack of substantial benefit in IBS-C versus placebo.
CONCLUSIONS: Our literature search indicates a lack of monotherapy treatment
options to adequately manage IBS-C patients, and the need for European focussed
burden of disease and COI studies, to address the evidence gaps identified in this
systematic literature search.
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OBJECTIVES: In patients with raised liver function tests (LFTs) but without clini-
cally apparent liver disease, the appropriate level of follow-up to take can be un-
clear. Our aim was to develop and validate a prediction model to estimate the risk
of one year all-cause mortality in patients with LFTs taken in primary care.
METHODS: A population-based retrospective cohort of patients, without clinically
apparent liver disease, in Tayside Scotland was identified as having their first LFTs
performed in primary care and followed for one year. Biochemistry data were
record-linked to secondary care, prescriptions and mortality data to ascertain
baseline characteristics including LFTs, age, gender, deprivation, comorbidities,
alcohol and drug dependency, methadone use, and statin, NSAIDs or antibiotic use.
Multiple imputation was used to impute missing values for LFTs. Parametric accel-
erated failure time survival models were fitted to predict all-cause mortality. The
final model was assessed for discriminatory ability using the C-statistic. A separate
validation cohort was obtained from 19 general practices across Scotland to exter-
nally validate the final model. RESULTS: Predictors of all-cause mortality model
included male gender, age, social deprivation, history of cancer, renal disease,
stroke, ischaemic heart disease and respiratory disease, statin use, and all LFTs. A
model integrating these predictors had excellent discriminatory ability (C-statistic
(95% CI)  0.82 (0.80, 0.84)) and calibrated well internally. The external validation
had a C-statistic of 0.86 (0.79, 0.90) with very good calibration. The model without
LFTs had a C-statistic of 0.63 (95% CI 0.61, 0.66). CONCLUSIONS: This study has
developed and externally validated a model that predicts risk of mortality in pa-
tients with no apparent liver disease but tested for LFTs in primary care. This model
can be used in practice by general practitioners and others working in community
settings to improve management of these patients with the potential to save costs
to the health system.
Gastrointestinal Disorders – Cost Studies
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OBJECTIVES: Unmanaged dysphagia exposes patients to risk of malnutrition, de-
hydration, urinary tract infections (UTI) and aspiration pneumonia. It has been
demonstrated that dysphagia screening and management may reduce the risk of
developing complications and incurring increased hospital charges. The objective
of this analysis is to quantify the additional charges associated with common
complications of dysphagia. METHODS: Using 2008 Health Care Utilization Project
(HCUP) data, individuals with a recorded diagnosis of dysphagia (ICD-9 CM: 438.82,
787.2-787.29) were identified. The mean (10% trimmed) hospital charges for indi-
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viduals with and without a recorded comorbid diagnosis of malnutrition, dehydra-
tion, UTI and aspiration pneumonia were compared. As there was a significant
interaction between number of comorbidities and hospital charge in the UTI and
pneumonia sample, an analysis of covariance (ANCOVA) model was employed to
adjust the UTI and pneumonia analyses for this influence. The model was adjusted
for complication diagnosis as a factor and both 1) number of comorbidities, and 2)
complication diagnosis and number of comorbidities interaction as covariates.
RESULTS: The most common complications reported in patients with a recorded
diagnosis of dysphagia were UTI (27%, n3424), pneumonia (26%, n3348), dehy-
dration (12%, n1507), and malnutrition (8%, n1027). Dysphagia patients with
complications had significantly higher mean hospital charges than those without
the complications UTI ($35,358 vs. $30,373, p0.001), pneumonia ($33,085 vs.
$31,184, p0.001), dehydration ($28,093 vs. $20,850, p0.001), and malnutrition
($37,192 vs. $34,747, p0.001), and MS ($32,406 vs. $23,726, p0.001).
CONCLUSIONS: Our results demonstrate that having to treat the complications of
dysphagia adds significantly to the cost of hospital care. Proactive management of
patients with dysphagia may confer substantial savings to hospitals.
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OBJECTIVES: To investigate the cost and incidence of adverse gastrointestinal (GI)
events caused by bisphosphonate therapy in Taiwan. METHODS: We conducted a
retrospective cohort study based on the National Health Insurance Research data-
base in Taiwan from 2005 to 2009. The inclusion criteria for the study cases were
patients 1) who sought inpatient or outpatient care for gastrointestinal problems
with ICD9-CM codes of GI-related diagnosis within 4 months after the initiation of
filling bisphosphonate prescription (the index date) for bisphosphonate, and 2)
who have no prior history of GI treatment 90 days before the index date. The costs
and incidence associated with GI adverse events were assessed based upon sur-
vival analysis and generalized linear models. RESULTS: A total of 114,086 patients
were included in this study. The GI incidence rate was lower in the group treated
with risedronate (16%) than alendronate (25%). The average time of onset of GI
event was longer after taking risedronate (1.6 months) than taking alendronate (1
month). The average direct medical cost associated with a GI event was $3147(USD)
and $6235 (USD) in group treated with risedronate and alendronate, respectively.
The distribution of costs of GI events was physician consultation fees (35%), exam-
ination fee (10%), drug costs including proton pump inhibitors (22%), H2-blocker
(14%), cytoprotectants (7%) and other GI related costs (12%). CONCLUSIONS: Bis-
phosphonate treatment of osteoporosis may involve adverse GI events and their
associated medical costs should be taken into account when evaluate cost-effec-
tiveness of treatment for osteoporosis.
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OBJECTIVES: Dysphagia has been previously shown to increase hospital length of
stay (LOS) (Altman et al, 2010). The objective of this study was to quantify the
difference in hospital charges between patients identified with and without dys-
phagia among commonly associated neuromuscular, neurologic and cardiovascu-
lar diseases. METHODS: Using 2008 Health Care Utilization Project (HCUP) data,
individuals with a hospital discharge diagnosis of stroke, Alzheimer’s disease (AD),
ALS, dementia, heart failure (HF), multiple sclerosis, cerebral palsy, Huntington’s
disease, and Parkinson’s disease (PD) were identified using ICD-9 CM diagnosis
codes. Within each disease state, the mean (10% trimmed) hospital charges for
individuals with a recorded diagnosis of dysphagia (ICD-9: 438.82, 787.2-787.29)
were compared to those without dysphagia. An analysis of covariance (ANCOVA)
model was employed to account for potential impact of comorbidities on hospital
charges. The model was adjusted for dysphagia diagnosis as a factor and both 1)
number of comorbidities, and 2) dysphagia diagnosis and number of comorbidities
interaction as covariates. RESULTS: Dyphasgia was most commonly diagnosed in
patients with stroke (41.2%, n11,736), dementia (0.6%, n1,126), AD (0.4%, n489)
and HF (0.3%, n2,087). Cerebral palsy, PD, HD, and ALS were excluded from the
analysis due to small dysphagia sample (n10). Patients with dysphagia demon-
strated higher mean hospital charges compared with non-dysphagia patients for
stroke ($32,531 vs. $26,004, p0.001), dementia ($26,836 vs. $23,445, p0.001), AD
($25,431 vs. $22,915, p0.001), HF ($30,686 vs. $26,984, p0.001), and MS ($32,406 vs.
$23,726, p0.001) adjusted for number of comorbidities. The magnitude and direc-
tion of the association between dysphagia and hospital charges were consistent in
both the bivariate and multivariate analyses. CONCLUSIONS: Our results demon-
strate that patients with conditions that are complicated by dysphagia cost hospi-
tals significantly more than similar patients without dysphagia and management
of these patients can avert significant costs.
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OBJECTIVES: Generic prescribing is important in South Africa. Many medical aid
schemes will only reimburse the cost of the generic product, and a co-payment is
required if a patient wants to use the originator product. The primary aim of this
study was to investigate originator versus generic prescribing focussing on proton
pump inhibitors (PPIs). METHODS: Prescription data were obtained from a private
medical aid administrator in South Africa. The data covered 2010 and included
medication, procedures and devices (a total of 2126264 records). For the purpose of
this study, only PPI medicine items were extracted and analysed (MIMS category
12.4.4). Basic descriptive statistics were calculated. RESULTS: A total of 20537 PPIs
were prescribed (only 18.56% on the chronic option of the medical aid schemes).
Five different PPI active ingredients were prescribed to 7060 patients (50.88% fe-
male patients). Omeprazole was the most often prescribed PPI, accounting for half
of all PPI prescribing (50.78%), followed by esomeprazole (19.83%) and lansoprazole
(18.04%). Eight different trade names of omeprazole were prescribed (one generic
product accounted for 56.00% of all omeprazole prescriptions and 56.08% of the
cost of omeprazole prescriptions). The originator product only accounted for 1.75%
of omeprazole prescribing frequency and 3.07% of prescribing cost. Only one trade
name of esomeprazole was prescribed (no generic equivalents) and nine trade
names of lansoprazole (the originator accounted for 1.43% of prescribing frequency
and 2.51% of cost). On average, esomeprazole had the highest average cost of
R308.97, followed by rabeprazole (R236.58). Both these products do not have generic
equivalents on the South African market. CONCLUSIONS: Further studies that
include dosage forms and prescribed daily doses (PDDs) should be conducted
alongside cost analyses. A clear difference between the prescribing and cost of
originator versus generic prescribing was detected in this study.
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OBJECTIVES: To determine the cost range for different forms of antyhelicobacter
therapy (first and second line) of the working age patients with gastric and duode-
num ulcer in Ukraine. METHODS: Different variants of (triple and quadrotherapy)
of traditional schemes of antihelicobacter therapy, recommended by “Maastriht”
(2005) have been used in the research. When treatment course costs determination
for antihelicobacter therapy for one patient, the expenses only for drugs included
in the tested schemes have been taken. The prices for drugs have been taken from
the information system “Medicinal preparations”, Morion Company (August 2010).
The currency rate to dollar (USA) on August 31, 2010 was 7,89:1. Medicinal prepa-
rations with minimal and maximal costs for the disease treatment course have
been included for the costs range evaluation for the course of antihelicobacter
therapy of the first and second line for one patient. RESULTS: The costs range of
antihelicobacter therapy of the first and second line in Ukraine is rather large, $
5,71– $ 238,55 and $ 5,78 – $ 149,26, respectively. It is connected with big difference
between the cost of original and generic drugs, included into antihelicobacter ther-
apy scheme. CONCLUSIONS: The cost for antihelicobacter gastric ulcer and duo-
denal therapy course with the use of original and foreign generics can be rather
high in Ukraine. In connection with it, when drugs choosing it is reasonable to use
pharmacoeconomics research results, that will help to optimize the state, insuar-
ing componies and patients expenses for the disease treatment.
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OBJECTIVES: To compare health care costs between patients who switched from a
branded proton pump inhibitor (PPI) to a generic PPI and vice versa.METHODS:We
conducted a retrospective database analysis using commercial enrollees from a
large US health plan from February 2008 to March 2010. Continuously eligible adult
patients who had gastroesophageal reflux disease (GERD) or GERD-related condi-
tions, and evidence of PPI use during February 2009 to September 2009 were in-
cluded. The index PPI was defined as the first PPI prescribed during the identifica-
tion period. The two cohorts in this study included patients who switched from a
generic PPI to a branded index PPI versus patients who switched from a branded
index PPI to a generic index PPI. Risk adjustment was performed using propensity
score matching. We controlled for age, gender, region, GERD severity, plan, pre-
index Quan-Charlson comorbidity score (CCI), baseline daily average consumption
(DACON), and baseline costs and utilization.RESULTS:A total of 9881 patients from
each cohort were matched after propensity score matching. During the 6 months
after the switch, there were no statistically significant differences between the two
cohorts in terms of office visit costs, outpatient costs, emergency services costs,
inpatient costs, and other costs., However, patients who switched to a generic PPI
had lower pharmacy costs ($1919 vs. $2306, p0.001). CONCLUSIONS: Although
pharmacy costs are slightly lower for patients who switched from a branded to a
generic PPI, there were no significant differences in other health care costs such as
for office visits, emergency room services, and inpatient visits.
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